NYSEAMERICAN:BPMX - Biopharmx Stock Price, Forecast & News

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

Biopharmx's stock reverse split on Friday, April 26th 2019. The 1-25 reverse split was announced on Monday, April 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 25th 2019. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 4 shares after the split.

Biopharmx Corp (NYSEAMERICAN:BPMX) issued its quarterly earnings results on Tuesday, December, 10th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.08. View Biopharmx's Earnings History.

Biopharmx is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Biopharmx.

1 equities research analysts have issued 1-year price targets for Biopharmx's shares. Their forecasts range from $1.00 to $1.00. On average, they expect Biopharmx's share price to reach $1.00 in the next year. This suggests a possible upside of 112.8% from the stock's current price. View Analyst Price Targets for Biopharmx.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx.

Media headlines about BPMX stock have trended somewhat negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biopharmx earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Biopharmx.

Some companies that are related to Biopharmx include Bio-Gene Technology (BGT), Navidea Biopharmaceuticals (NAVB), Exopharm (EX1), Aerpio Pharmaceuticals (ARPO), Proteomics Int Lab (PIQ), ImmuPharma (IMM), Race Oncology (RAC), Immuron (IMC), Prescient Therapeutics (PTX), Agronomics (ANIC), Inhibitor Therapeutics (INTI), Oragenics (OGEN), Oragenics (OGEN), Quest PharmaTech (QPT) and Microbix Biosystems (MBX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), CytRx (CYTR), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Protalix Biotherapeutics (PLX) and Aurinia Pharmaceuticals (AUPH).

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BPMX stock can currently be purchased for approximately $0.47.

Biopharmx has a market capitalization of $6.67 million. Biopharmx employs 17 workers across the globe.View Additional Information About Biopharmx.

The official website for Biopharmx is http://www.biopharmx.com/.

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.